1
|
Villa D, Hoster E, Hermine O, Klapper W, Szymczyk M, Bosly A, Unterhalt M, Freeman CL, Scott DW, Gerrie AS, Savage KJ, Sehn LH, Dreyling M. RITUXIMAB IN COMBINATION WITH BENDAMUSTINE OR HIGH‐DOSE CYTARABINE‐BASED INDUCTION THERAPY IN TRANSPLANT‐ELIGIBLE PATIENTS WITH MANTLE CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.62_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- D. Villa
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - E. Hoster
- Ludwig‐Maximilians‐Universität München Institute for Medical Information Processing, Biometry, and Epidemiology Munich Germany
| | - O. Hermine
- University of Paris Descartes, Hôpital Necker Assistance Publique Hôpitaux de Paris Paris France
| | - W. Klapper
- Universitätsklinikum Schleswig‐Holstein Institut für Pathologie, Sektion Hämatopathologie und Lymphknotenregister Kiel Germany
| | - M. Szymczyk
- Maria Sklodowska‐Curie National Research Institute of Oncology Department of Lymphoid Malignancies Warsaw Poland
| | - A. Bosly
- CHU UCL Mont‐Godinne‐Dinant Faculty of Medicine and Dentistry Yvoir Belgium
| | - M. Unterhalt
- University of Ulm Department of Internal Medicine Ulm Germany
| | - C. L. Freeman
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - D. W. Scott
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - A. S. Gerrie
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - K. J. Savage
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - L. H. Sehn
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - M. Dreyling
- Ludwig‐Maximilians‐Universität München Medizinische Klinik III Munich Germany
| |
Collapse
|
2
|
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Rossi D, Dirnhofer S, Ceriani L, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.78_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Stathis
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - U. Mey
- Oncology and Hematology; Kantonsspital Graubuenden; Chur Switzerland
| | - S. Schär
- Coordinating Center; SAKK; Bern Switzerland
| | - F. Hitz
- Oncology/Hematology; Kantonsspital St.Gallen; St.Gallen Switzerland
| | - C. Pott
- Medizinischen Klinik II Hämatologie und Internistische Onkologie; Universitätsklinikum Schleswig-Holstein; Campus Kiel Kiel Germany
| | - N. Mach
- Service d'Oncologie; Département d'Oncologie, Hôpitaux Universitaires de Genève; Genève Switzerland
| | - F. Krasniqi
- Medical Oncology; University Hospital of Basel; Basel Switzerland
| | - U. Novak
- Department of Medical Oncology; Inselspital / Bern University Hospital; Bern Switzerland
| | - C. Schmidt
- Department of Medicine III; University of Munich; Munich Germany
| | - K. Hohloch
- Oncology and Hematology; Kantonsspital Graubuenden; Chur Switzerland
| | - D. Kienle
- Oncology and Hematology; Kantonsspital Graubuenden; Chur Switzerland
| | - D. Hess
- Oncology/Hematology; Kantonsspital St.Gallen; St.Gallen Switzerland
| | - A. Moccia
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Unterhalt
- Department of Medicine III; University of Munich; Munich Germany
| | | | - S. Hayoz
- Coordinating Center; SAKK; Bern Switzerland
| | - D. Rossi
- Laboratory of Experimental Hematology; Institute of Oncology Research; Bellinzona Switzerland
| | - S. Dirnhofer
- Pathologie; Universitätsspital Basel; Basel Switzerland
| | - L. Ceriani
- Nuclear Medicine and PET-CT centre; Imaging Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Bertoni
- Lymphoma Genomics; Institute of Oncology Research; Bellinzona Switzerland
| | - C. Buske
- CCC Ulm; University Hospital Ulm; Ulm Germany
| | - E. Zucca
- Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - W. Hiddemann
- Department of Medicine III; University of Munich; Munich Germany
| |
Collapse
|
3
|
Zoellner A, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, Kluin-Nelemans H, Hiddemann W, Dreyling M, Hoster E. AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION SIGNIFICANTLY PROLONGS PROGRESSION-FREE AND OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.13_2629] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Zoellner
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - M. Unterhalt
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - S. Stilgenbauer
- Department of Internal Medicine I; University Hospital of Homburg; Homburg Germany
| | - K. Hübel
- Department of Medicine I; University Hospital of Cologne; Cologne Germany
| | - C. Thieblemont
- Hemato-Oncology Department; Diderot University; Hôpital Saint-Louis Paris France
| | - B. Metzner
- Department of Hematology/Oncology; University Hospital Oldenburg; Oldenburg Germany
| | | | - W. Hiddemann
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - M. Dreyling
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - E. Hoster
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| |
Collapse
|
4
|
Hoster E, Unterhalt M, Hänel M, Prange-Krex G, Forstpointner R, Florschütz A, Graeven U, Frickhofen N, Wulf G, Lengfelder E, Lerchenmüller C, Schlag R, Dierlamm J, Fischer Von Weikersthal L, Ahmed A, Harich H, Rosenwald A, Klapper W, Dreyling M, Hiddemann W, Herold M. RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_12] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- E. Hoster
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - M. Unterhalt
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - M. Hänel
- Klinik für Innere Medizin III; Klinikum Chemnitz; Chemnitz Germany
| | - G. Prange-Krex
- Innere Medizin, Hämatologie, Onkologie, Gemeinschaftspraxis; Dresden Germany
| | - R. Forstpointner
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - A. Florschütz
- Klinik für Innere Medizin; Städtisches Klinikum Dessau; Dessau Germany
| | - U. Graeven
- Klinik für Hämatologie, Onkologie und Gastroenterologie; Kliniken Maria Hilf; Mönchengladbach Germany
| | - N. Frickhofen
- Klinik Innere Medizin III; HELIOS Dr. Horst Schmidt Kliniken Wiesbaden; Wiesbaden Germany
| | - G. Wulf
- Hämatologie und Medizinische Onkologie; Universitätsmedizin Göttingen; Göttingen Germany
| | - E. Lengfelder
- III. Medizinische Klinik; Klinikum Mannheim; Mannheim Germany
| | | | - R. Schlag
- Innere Medizin, Hämatologie u. Internistische Onkologie; Gemeinschaftspraxis; Würzburg Germany
| | - J. Dierlamm
- II. Medizinischen Klinik und Poliklinik; Universitätsklinikum Eppendorf; Hamburg Germany
| | | | - A. Ahmed
- Medizinische Klinik III; Städtisches Klinikum Braunschweig; Braunschweig Germany
| | - H. Harich
- Onkologie Hof, Medizinisches Versorgungszentrum; Hof Germany
| | - A. Rosenwald
- Institut für Pathologie; Universität Würzburg; Würzburg Germany
| | - W. Klapper
- Sektion Hämatopathologie und Lymphknotenregister; Universitätsklinikum Schleswig-Holstein; Kiel Germany
| | - M. Dreyling
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - W. Hiddemann
- Medizinische Klinik III; Klinikum der Ludwig-Maximilians-Universität München; Munich Germany
| | - M. Herold
- Onkologisches Zentrum; HELIOS Klinikum Erfurt; Erfurt Germany
| |
Collapse
|
5
|
Alig S, Jurinovic V, Dreyling M, Pastore A, Kridel R, Gascoyne R, Hiddemann W, Unterhalt M, Hoster E, Weigert O. HIGHER MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_86] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- S. Alig
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| | - V. Jurinovic
- Medical Department III & Institute for Medical Informatics, Biometry and Epidemiology; Ludwig-Maximilians-University; Munich Germany
| | - M. Dreyling
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| | - A. Pastore
- Human Oncology and Pathogenesis Program; Memorial Sloan Kettering Cancer Center; New York USA
| | - R. Kridel
- Division of Medical Oncology and Hematology; Princess Margaret Cancer Centre - University Health Network; Toronto Canada
| | - R. Gascoyne
- Centre for Lymphoid Cancer & Department of Pathology and Laboratory Medicine, BC Cancer Agency; Vancouver Canada
| | - W. Hiddemann
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| | - M. Unterhalt
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| | - E. Hoster
- Medical Department III & Institute for Medical Informatics, Biometry and Epidemiology; Ludwig-Maximilians-University; Munich Germany
| | - O. Weigert
- Medical Department III; Ludwig-Maximilians-University; Munich Germany
| |
Collapse
|
6
|
Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, Hansmann M, Bernd W, Stein H, Pöschel V, Dreyling M, Trümper L, Löffler M, Schmitz N, Hiddemann W, Pfreundschuh M, Klapper W. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol 2016; 27:1323-9. [DOI: 10.1093/annonc/mdw185] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2016] [Accepted: 04/22/2016] [Indexed: 11/14/2022] Open
|
7
|
Leich E, Hoster E, Wartenberg M, Unterhalt M, Siebert R, Koch K, Klapper W, Engelhard M, Puppe B, Horn H, Staiger AM, Stuhlmann-Laeisz C, Bernd HW, Feller AC, Hummel M, Lenze D, Stein H, Hartmann S, Hansmann ML, Möller P, Hiddemann W, Dreyling M, Ott G, Rosenwald A. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia 2015; 30:854-60. [PMID: 26621338 DOI: 10.1038/leu.2015.330] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Revised: 11/05/2015] [Accepted: 11/13/2015] [Indexed: 01/18/2023]
Abstract
Approximately 15% of follicular lymphomas (FLs) lack breaks in the BCL2 locus. The aim of this study was to better define molecular and clinical features of BCL2-breakpoint/t(14;18)-negative FLs. We studied the presence of BCL2, BCL6 and MYC breaks by fluorescence in situ hybridization and the expression of BCL2, MUM1, CD10, P53 and Ki67 in large clinical trial cohorts of 540 advanced-stage FL cases and 116 early-stage disease FL patients treated with chemotherapy regimens and radiation, respectively. A total of 86% and 53% of advanced- and early-stage FLs were BCL2-breakpoint-positive, respectively. BCL2 was expressed in almost all FLs with BCL2 break and also in 86% and 69% of BCL2-breakpoint-negative advanced- and early-stage FLs, respectively. CD10 expression was significantly reduced in BCL2-breakpoint-negative FLs of all stages and MUM1 and Ki67 expression were significantly increased in BCL2-break-negative early-stage FLs. Patient characteristics did not differ between FLs with and without BCL2 breaks and neither did survival times in advanced-stage FLs. These results suggest that the molecular profile differs to some extent between FLs with and without BCL2 breaks and support the notion that FLs with and without BCL2 breaks belong to the same lymphoma entity.
Collapse
Affiliation(s)
- E Leich
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - E Hoster
- Institute of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany
| | - M Wartenberg
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - M Unterhalt
- Department of Internal Medicine III, University Hospital Munich, Munich, Germany
| | - R Siebert
- Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
| | - K Koch
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany
| | - W Klapper
- Institute of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany
| | - M Engelhard
- Department for Radiotherapy, University Hospital Essen, Essen, Germany
| | - B Puppe
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | - H Horn
- Margarete Fischer-Bosch Institute of Clinical Pharmacology, Robert-Bosch-Krankenhaus, Stuttgart and University of Tübingen, Tübingen, Germany
| | - A M Staiger
- Margarete Fischer-Bosch Institute of Clinical Pharmacology, Robert-Bosch-Krankenhaus, Stuttgart and University of Tübingen, Tübingen, Germany
| | - C Stuhlmann-Laeisz
- Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
| | - H W Bernd
- Institute of Pathology, University Hospital Schleswig-Holstein, Lübeck, Germany
| | - A C Feller
- Institute of Pathology, University Hospital Schleswig-Holstein, Lübeck, Germany
| | - M Hummel
- Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin, Berlin, Germany
| | - D Lenze
- Institute of Pathology, Campus Benjamin Franklin, Charité Universitätsmedizin, Berlin, Germany
| | - H Stein
- Pathodiagnostik Berlin, Berlin, Germany
| | - S Hartmann
- Institute of Pathology, University Hospital Frankfurt am, Frankfurt, Germany
| | - M L Hansmann
- Institute of Pathology, University Hospital Frankfurt am, Frankfurt, Germany
| | - P Möller
- Institute of Pathology, University Hospital Ulm, Ulm, Germany
| | - W Hiddemann
- Department of Internal Medicine III, University Hospital Munich, Munich, Germany
| | - M Dreyling
- Department of Internal Medicine III, University Hospital Munich, Munich, Germany
| | - G Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany
| | - A Rosenwald
- Institute of Pathology, University of Würzburg, Würzburg, Germany.,Comprehensive Cancer Center Mainfranken (CCC MF), Würzburg, Germany
| | | |
Collapse
|
8
|
Ferrero S, Pastore A, Scholz CW, Forstpointner R, Pezzutto A, Bergmann L, Trümper L, Finke J, Keller U, Ghione P, Passera R, Hiddemann W, Weigert O, Unterhalt M, Dreyling M. Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial. Leukemia 2015; 30:984-7. [DOI: 10.1038/leu.2015.215] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
9
|
Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367:520-31. [PMID: 22873532 DOI: 10.1056/nejmoa1200920] [Citation(s) in RCA: 361] [Impact Index Per Article: 30.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission. METHODS We randomly assigned patients 60 years of age or older with mantle-cell lymphoma, stage II to IV, who were not eligible for high-dose therapy to six cycles of rituximab, fludarabine, and cyclophosphamide (R-FC) every 28 days or to eight cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 21 days. Patients who had a response underwent a second randomization to maintenance therapy with rituximab or interferon alfa, each given until progression. RESULTS Of the 560 patients enrolled, 532 were included in the intention-to-treat analysis for response, and 485 in the primary analysis for response. The median age was 70 years. Although complete-remission rates were similar with R-FC and R-CHOP (40% and 34%, respectively; P=0.10), progressive disease was more frequent with R-FC (14%, vs. 5% with R-CHOP). Overall survival was significantly shorter with R-FC than with R-CHOP (4-year survival rate, 47% vs. 62%; P=0.005), and more patients in the R-FC group died during the first remission (10% vs. 4%). Hematologic toxic effects occurred more frequently in the R-FC group than in the R-CHOP group, but the frequency of grade 3 or 4 infections was balanced (17% and 14%, respectively). In 274 of the 316 patients who were randomly assigned to maintenance therapy, rituximab reduced the risk of progression or death by 45% (in remission after 4 years, 58%, vs. 29% with interferon alfa; hazard ratio for progression or death, 0.55; 95% confidence interval, 0.36 to 0.87; P=0.01). Among patients who had a response to R-CHOP, maintenance therapy with rituximab significantly improved overall survival (4-year survival rate, 87%, vs. 63% with interferon alfa; P=0.005). CONCLUSIONS R-CHOP induction followed by maintenance therapy with rituximab is effective for older patients with mantle-cell lymphoma. (Funded by the European Commission and others; ClinicalTrials.gov number, NCT00209209.).
Collapse
Affiliation(s)
- H C Kluin-Nelemans
- Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig WD, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M, Hiddemann W. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2008; 23:153-61. [PMID: 18818699 DOI: 10.1038/leu.2008.261] [Citation(s) in RCA: 129] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34) or CHOP (n=30). R-CHOP resulted in significantly higher overall response (OR) rate (94 vs 67%, P=0.0085) in the LPL patients and in the WM subgroup (91 vs 60%, P=0.0188). With a median observation time of 42 months, R-CHOP induced a significantly longer time to treatment failure (TTF) with a median of 63 months for R-CHOP vs 22 months in the CHOP arm in the LPL patients (P=0.0033) and in the WM subgroup (P=0.0241). There was no major difference of treatment-associated toxicity between both treatment groups. These data indicate that the addition of rituximab to front-line chemotherapy improves treatment outcome in patients with LPL or WM.
Collapse
Affiliation(s)
- C Buske
- Department of Internal Medicine III, University of Munich, Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Bottcher S, Ritgen M, Buske S, Gesk S, Klapper W, Hoster E, Hiddemann W, Unterhalt M, Dreyling M, Siebert R, Kneba M, Pott C. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 2008; 93:551-9. [DOI: 10.3324/haematol.11267] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
12
|
Schneider F, Bohlander SK, Schneider S, Papadaki C, Kakadyia P, Dufour A, Vempati S, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Wandt H, Hiddemann W, Spiekermann K. AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia. Leukemia 2007; 21:2199-201. [PMID: 17625612 DOI: 10.1038/sj.leu.2404830] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
13
|
Abstract
Mantle cell lymphoma is characterized by an aggressive clinical course and poor prognosis, with only few long-term survivors. Conventional chemotherapy has failed to substantially alter the natural course of the disease and remains a palliative approach. However, several randomized trials have recently clearly demonstrated the superiority of a combined immunochemotherapy containing the anti-CD20 antibody rituximab. In addition, a randomized trial has shown a significantly improved progression-free survival after myeloablative radiochemotherapy with autologous stem cell transplantation similar to other dose-intensified approaches (hyper-CVAD). Unfortunately, the vast majority of patients will eventually relapse. However, numerous molecular targeting strategies (e.g. proteasome inhibitors, immunomodulatory drugs or radiolabeled antibodies) have achieved promising results in early phase II studies.
Collapse
Affiliation(s)
- M Dreyling
- Med. Klinik und Poliklinik III, Klinikum der Universität München-Grosshadern, Marchioninistrasse 15, 81377, München, Deutschland.
| | | | | | | |
Collapse
|
14
|
Abstract
The treatment options for patients with follicular lymphoma have substantially improved in the last years, in particular with the development of innovative, antibody-based therapeutic strategies. Thus, the anti-CD20 antibody rituximab is one of the cornerstones in the therapy of follicular lymphoma today. It is used in combination with chemotherapy or as a single agent therapy for remission induction and as maintenance therapy. Encouraging results were also reported from monoclonal anti-CD20 antibodies, which are conjugated to radionuclides and exploit the high radiosensitivity of lymphomas. An example for this is the anti-CD20 antibody ibritumomab tiuxetan, which is coupled to 90Yttrium and shows comparable activity to rituximab. Current trials are underway testing whether, for example, the sequential application of a rituximab/chemotherapy induction, myeloablative consolidation therapy followed by autologous stem cell transplantation and rituximab maintenance further improves the therapeutic outcome in follicular lymphoma, or even has curative potential in a subgroup of patients with this disease.
Collapse
Affiliation(s)
- C Buske
- Med. Klinik und Poliklinik III, Klinikum der Universität München-Grosshadern, Marchioninistr. 15, 81377, München, Deutschland.
| | | | | |
Collapse
|
15
|
Affiliation(s)
- W Hiddemann
- Department of Internal Medicine III, University of Munich, Munich, Germany
| | | |
Collapse
|
16
|
Nickenig C, Dreyling M, Hoster E, Ludwig WD, Dörken B, Freund M, Huber C, Ganser A, Trümper L, Forstpointner R, Unterhalt M, Hiddemann W. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas—results of a randomized comparison by the German Low-Grade Lymphoma Study Group. Ann Oncol 2007; 18:136-142. [PMID: 17071931 DOI: 10.1093/annonc/mdl348] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Myeloablative radio-chemotherapy with subsequent autologous stem cell transplantation (ASCT) significantly prolongs progression free and probably overall survival in follicular lymphoma (FL) in first remission. The current trial explored prospectively the rate of successful stem cell mobilization in patients with advanced stage FL after initial therapy with either Mitoxantrone, Chlorambucil, Prednisone (MCP) or Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) as part of a prospective randomized comparison of both regimens. ASCT patients received Dexa-BEAM (Dexamethasone, BCNU, Melphalan, Etoposide, Cytarabine) for mobilization of stem cells. Stem cells were collected and a minimum of 2x2.0x106/kg bw CD34+ was required for ASCT. Of 79 evaluable patients, 58 (73%) had follicular lymphoma, 13 (16%) mantle cell lymphoma and 8 (10%) lymphoplasmacytic lymphoma. In the 45 patients assigned to CHOP, stem cell collection was successful in 42 cases (93%, 95% CI 82% to 99%). This high mobilization rate after CHOP could be confirmed in 61 subsequent patients (87%). In contrast, after MCP therapy stem cell collection was successful in only 15 of 34 patients (44%, 95% CI 27% to 62%; P=0.0003). In conclusion, initial therapy with MCP significantly impairs the ability to collect stem cells and should be avoided for first line therapy of younger patients potentially qualifying for high dose consolidation and ASCT in first remission.
Collapse
Affiliation(s)
- C Nickenig
- Department of Internal Medicine III, Ludwig-Maximilians University, Munich Grosshadern
| | - M Dreyling
- Department of Internal Medicine III, Ludwig-Maximilians University, Munich Grosshadern
| | - E Hoster
- Department of Internal Medicine III, Ludwig-Maximilians University, Munich Grosshadern; Institute of Medical Informatics, Biometry and Epidemiology, University of Munich
| | - W-D Ludwig
- Department of Hematology and Oncology, Charité Campus Berlin-Buch
| | - B Dörken
- Department of Hematology and Oncology, Charité Berlin Campus Virchow-Klinikum
| | - M Freund
- Division of Hematology and Oncology, University Rostock
| | - C Huber
- Department of Internal Medicine III, University of Mainz
| | - A Ganser
- Department of Hematology, Hemostasis and Oncology, Hannover Medical School
| | - L Trümper
- Department of Hematology and Oncology, Georg-August University, Göttingen, Germany
| | - R Forstpointner
- Department of Internal Medicine III, Ludwig-Maximilians University, Munich Grosshadern
| | - M Unterhalt
- Department of Internal Medicine III, Ludwig-Maximilians University, Munich Grosshadern
| | - W Hiddemann
- Department of Internal Medicine III, Ludwig-Maximilians University, Munich Grosshadern.
| |
Collapse
|
17
|
Weigert O, Jurczak W, Von Schilling C, Giza A, Rummel M, Hubalewska A, Pezzutto A, Unterhalt M, Hiddemann W, Skotnicki A, Dreyling M. Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: Results of two phase II trials of the European MCL Network and the PLRG. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7533] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7533 Background: Radioimmunotherapy (RIT) has demonstrated high clinical efficacy in follicular lymphoma but varying results in mantle cell lymphoma (MCL). Methods: We performed a comparative analysis of two phase II studies with similar inclusion criteria to identify potential predictors of response. 32 patients with relapsed or refractory MCL, WHO performance status ≤2, appropriate hematopoesis (ANC > 1,500/mm3, platelets > 100,000/mm3) and adequate function of liver and kidneys were treated with RIT upfront (Arm A, n = 16) or as consolidation after initial cytoreduction (Arm B, n = 16). 28 patients (88%) had been previously treated with rituximab. Patients with >25% bone marrow involvement, known CNS lymphoma, HIV infection or other severe concurrent disease were excluded. Ibritumomab tiuxetan (Zevalin) was applied at a dose of 15 MBq 90Y/kg, whereas patients with reduced platelet counts (<150,000/mm3) received 11 MBq 90Y/kg. Results: The median age was 66.9 years (range 58–72) in Arm A and 63.1 years (range 45–79) in Arm B. The median number of prior regimens was 4 (range 2–6) in Arm A and 1 (1–5) in Arm B. RIT treatment was generally well tolerated with the most common toxicities being hematologic. Thrombocytopenia grade 3 and 4 was observed in 69% of patients, one patient died of hemorrhagic stroke. Granulocytopenia grade 4 occurred in 34% of patients, one patient developed a grade 4 infectious complication. Currently 22 patients are evaluable for response rate and duration of remission (DR). In Arm A a partial response (PR) was observed in 2 of 6 evaluable patients (33.3%) with a median DR of 3.9 months only. In Arm B chemoinduction achieved 2 complete responses (CR) and 14 PR. Following RIT seven of 14 PR patients (50%) converted to CR. Currently, 13 of 16 patients (81%) are still in remission. As expected the most important adverse risk factor was bulky disease before RIT with no responses seen in this patient population. Patients with less prior therapeutic lines (< 2) had significantly higher response rates. Conclusions: In future trials, RIT should be applied earlier in the treatment algorithm of MCL after a debulking strategy with combined immuno-chemotherapy. [Table: see text]
Collapse
Affiliation(s)
- O. Weigert
- University Hospital Grosshadern, Munich, Germany; Department of Hematology, Crakow, Poland; University Hospital, Munich, Germany; University Hospital, Frankfurt, Germany; Department of Nuclear Medicine CMUJ, Cracow, Poland; Charité Campus Buch, Berlin, Germany
| | - W. Jurczak
- University Hospital Grosshadern, Munich, Germany; Department of Hematology, Crakow, Poland; University Hospital, Munich, Germany; University Hospital, Frankfurt, Germany; Department of Nuclear Medicine CMUJ, Cracow, Poland; Charité Campus Buch, Berlin, Germany
| | - C. Von Schilling
- University Hospital Grosshadern, Munich, Germany; Department of Hematology, Crakow, Poland; University Hospital, Munich, Germany; University Hospital, Frankfurt, Germany; Department of Nuclear Medicine CMUJ, Cracow, Poland; Charité Campus Buch, Berlin, Germany
| | - A. Giza
- University Hospital Grosshadern, Munich, Germany; Department of Hematology, Crakow, Poland; University Hospital, Munich, Germany; University Hospital, Frankfurt, Germany; Department of Nuclear Medicine CMUJ, Cracow, Poland; Charité Campus Buch, Berlin, Germany
| | - M. Rummel
- University Hospital Grosshadern, Munich, Germany; Department of Hematology, Crakow, Poland; University Hospital, Munich, Germany; University Hospital, Frankfurt, Germany; Department of Nuclear Medicine CMUJ, Cracow, Poland; Charité Campus Buch, Berlin, Germany
| | - A. Hubalewska
- University Hospital Grosshadern, Munich, Germany; Department of Hematology, Crakow, Poland; University Hospital, Munich, Germany; University Hospital, Frankfurt, Germany; Department of Nuclear Medicine CMUJ, Cracow, Poland; Charité Campus Buch, Berlin, Germany
| | - A. Pezzutto
- University Hospital Grosshadern, Munich, Germany; Department of Hematology, Crakow, Poland; University Hospital, Munich, Germany; University Hospital, Frankfurt, Germany; Department of Nuclear Medicine CMUJ, Cracow, Poland; Charité Campus Buch, Berlin, Germany
| | - M. Unterhalt
- University Hospital Grosshadern, Munich, Germany; Department of Hematology, Crakow, Poland; University Hospital, Munich, Germany; University Hospital, Frankfurt, Germany; Department of Nuclear Medicine CMUJ, Cracow, Poland; Charité Campus Buch, Berlin, Germany
| | - W. Hiddemann
- University Hospital Grosshadern, Munich, Germany; Department of Hematology, Crakow, Poland; University Hospital, Munich, Germany; University Hospital, Frankfurt, Germany; Department of Nuclear Medicine CMUJ, Cracow, Poland; Charité Campus Buch, Berlin, Germany
| | - A. Skotnicki
- University Hospital Grosshadern, Munich, Germany; Department of Hematology, Crakow, Poland; University Hospital, Munich, Germany; University Hospital, Frankfurt, Germany; Department of Nuclear Medicine CMUJ, Cracow, Poland; Charité Campus Buch, Berlin, Germany
| | - M. Dreyling
- University Hospital Grosshadern, Munich, Germany; Department of Hematology, Crakow, Poland; University Hospital, Munich, Germany; University Hospital, Frankfurt, Germany; Department of Nuclear Medicine CMUJ, Cracow, Poland; Charité Campus Buch, Berlin, Germany
| |
Collapse
|
18
|
Dreyling M, Forstpointner R, Gramatzki M, Böck H, Hänel M, Seymour J, Planker M, Dührsen U, Wilms K, Unterhalt M, Hiddemann W. Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7502] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7502 Background: Rituximab (R) prolongs the progression-free survival (PFS) in patients with follicular lymphoma (FL) when given either simultaneously with or as maintenance after chemotherapy only. Methods: In the current study the impact of R maintenance after remission induction with an R-containing combined immuno-chemotherapy (R-FCM) was evaluated. Patients with advanced stage relapsed or refractory FL and mantle cell lymphoma (MCL) were eligible. The study design comprized 4 courses of chemotherapy with Fludarabine (25 mg/m2/d days 1–3), Cyclophosphamide (200 mg/m2/d days 1–3) and Mitoxantrone (8 mg/m2/d day 1) (FCM) ± Rituximab (375 mg/m2/d day 0). Patients entering a complete (CR) or partial remission (PR) underwent a second randomization for R maintenance (4 weekly doses (375 mg/m2/d) at three and nine months after end of induction) or observation only. Randomization was stratified for histology, prior therapies (up to 2 lines vs. >2), induction (±R), and response (CR vs. PR). After improved outcome of the R-FCM arm had been observed in the initial 147 randomized patients, all subsequent patients received a combined immuno-chemotherapy induction. Results: 176 of 195 randomized cases are evaluable, 138 of whom had received an R-containing induction. In these patients (as well as the total group) the median PFS after end of induction has not been reached in the R-maintenance arm in contrast to 17 months in patients with no further treatment (p = 0.001). This improvement was seen both in FL (n = 81; p = 0,035) and MCL (n = 47; p = 0,049). More importantly, overall survival rate was also improved after R maintenance with borderline significance (3 y rate 82% vs. 55%; p = 0,056). No major sided effects of R maintenance have been observed and the rate of serious infections was similar in both study arms (p = 0.72). Conclusions: The final analysis of this study confirms that R maintenance after combined immuno-chemotherapy (R-FCM) is highly effective and improves the progression-free survival—with a strong trend towards improved overall survival—of patients with relapsed FL and MCL. [Table: see text]
Collapse
Affiliation(s)
- M. Dreyling
- University Hospital Grosshadern, Munich, Germany; University Hospital, Kiel, Germany; Practice, Offenbach, Germany; Hospital Küchwald, Chemnitz, Germany; Peter MacCallum Cancer Institute, East Melbourne, Australia; Hospital, Krefeld, Germany; University Hospital, Essen, Germany; University Hospital, Würzburg, Germany
| | - R. Forstpointner
- University Hospital Grosshadern, Munich, Germany; University Hospital, Kiel, Germany; Practice, Offenbach, Germany; Hospital Küchwald, Chemnitz, Germany; Peter MacCallum Cancer Institute, East Melbourne, Australia; Hospital, Krefeld, Germany; University Hospital, Essen, Germany; University Hospital, Würzburg, Germany
| | - M. Gramatzki
- University Hospital Grosshadern, Munich, Germany; University Hospital, Kiel, Germany; Practice, Offenbach, Germany; Hospital Küchwald, Chemnitz, Germany; Peter MacCallum Cancer Institute, East Melbourne, Australia; Hospital, Krefeld, Germany; University Hospital, Essen, Germany; University Hospital, Würzburg, Germany
| | - H. Böck
- University Hospital Grosshadern, Munich, Germany; University Hospital, Kiel, Germany; Practice, Offenbach, Germany; Hospital Küchwald, Chemnitz, Germany; Peter MacCallum Cancer Institute, East Melbourne, Australia; Hospital, Krefeld, Germany; University Hospital, Essen, Germany; University Hospital, Würzburg, Germany
| | - M. Hänel
- University Hospital Grosshadern, Munich, Germany; University Hospital, Kiel, Germany; Practice, Offenbach, Germany; Hospital Küchwald, Chemnitz, Germany; Peter MacCallum Cancer Institute, East Melbourne, Australia; Hospital, Krefeld, Germany; University Hospital, Essen, Germany; University Hospital, Würzburg, Germany
| | - J. Seymour
- University Hospital Grosshadern, Munich, Germany; University Hospital, Kiel, Germany; Practice, Offenbach, Germany; Hospital Küchwald, Chemnitz, Germany; Peter MacCallum Cancer Institute, East Melbourne, Australia; Hospital, Krefeld, Germany; University Hospital, Essen, Germany; University Hospital, Würzburg, Germany
| | - M. Planker
- University Hospital Grosshadern, Munich, Germany; University Hospital, Kiel, Germany; Practice, Offenbach, Germany; Hospital Küchwald, Chemnitz, Germany; Peter MacCallum Cancer Institute, East Melbourne, Australia; Hospital, Krefeld, Germany; University Hospital, Essen, Germany; University Hospital, Würzburg, Germany
| | - U. Dührsen
- University Hospital Grosshadern, Munich, Germany; University Hospital, Kiel, Germany; Practice, Offenbach, Germany; Hospital Küchwald, Chemnitz, Germany; Peter MacCallum Cancer Institute, East Melbourne, Australia; Hospital, Krefeld, Germany; University Hospital, Essen, Germany; University Hospital, Würzburg, Germany
| | - K. Wilms
- University Hospital Grosshadern, Munich, Germany; University Hospital, Kiel, Germany; Practice, Offenbach, Germany; Hospital Küchwald, Chemnitz, Germany; Peter MacCallum Cancer Institute, East Melbourne, Australia; Hospital, Krefeld, Germany; University Hospital, Essen, Germany; University Hospital, Würzburg, Germany
| | - M. Unterhalt
- University Hospital Grosshadern, Munich, Germany; University Hospital, Kiel, Germany; Practice, Offenbach, Germany; Hospital Küchwald, Chemnitz, Germany; Peter MacCallum Cancer Institute, East Melbourne, Australia; Hospital, Krefeld, Germany; University Hospital, Essen, Germany; University Hospital, Würzburg, Germany
| | - W. Hiddemann
- University Hospital Grosshadern, Munich, Germany; University Hospital, Kiel, Germany; Practice, Offenbach, Germany; Hospital Küchwald, Chemnitz, Germany; Peter MacCallum Cancer Institute, East Melbourne, Australia; Hospital, Krefeld, Germany; University Hospital, Essen, Germany; University Hospital, Würzburg, Germany
| |
Collapse
|
19
|
Weide R, Heymanns J, Thomalla J, Köppler H, Hess G, Aldaoud A, Schmitz S, Unterhalt M, Dreyling MH, Hiddemann W. Bendamustine/mitoxantrone/rituximab (BMR): A very effective and well tolerated immuno-chemotherapy for relapsed and refractory indolent lymphomas. Results of a multicentre phase-II study of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Weide
- Haematology/Oncology Group Practice, Koblenz, Germany; Johannes Gutenberg-University, Mainz, Germany; Haematology/Oncology Group Practice, Leipzig, Germany; Haematology/Oncology Group Practice, Cologne, Germany; Ludwig-Maximilians Univ, Munich, Germany
| | - J. Heymanns
- Haematology/Oncology Group Practice, Koblenz, Germany; Johannes Gutenberg-University, Mainz, Germany; Haematology/Oncology Group Practice, Leipzig, Germany; Haematology/Oncology Group Practice, Cologne, Germany; Ludwig-Maximilians Univ, Munich, Germany
| | - J. Thomalla
- Haematology/Oncology Group Practice, Koblenz, Germany; Johannes Gutenberg-University, Mainz, Germany; Haematology/Oncology Group Practice, Leipzig, Germany; Haematology/Oncology Group Practice, Cologne, Germany; Ludwig-Maximilians Univ, Munich, Germany
| | - H. Köppler
- Haematology/Oncology Group Practice, Koblenz, Germany; Johannes Gutenberg-University, Mainz, Germany; Haematology/Oncology Group Practice, Leipzig, Germany; Haematology/Oncology Group Practice, Cologne, Germany; Ludwig-Maximilians Univ, Munich, Germany
| | - G. Hess
- Haematology/Oncology Group Practice, Koblenz, Germany; Johannes Gutenberg-University, Mainz, Germany; Haematology/Oncology Group Practice, Leipzig, Germany; Haematology/Oncology Group Practice, Cologne, Germany; Ludwig-Maximilians Univ, Munich, Germany
| | - A. Aldaoud
- Haematology/Oncology Group Practice, Koblenz, Germany; Johannes Gutenberg-University, Mainz, Germany; Haematology/Oncology Group Practice, Leipzig, Germany; Haematology/Oncology Group Practice, Cologne, Germany; Ludwig-Maximilians Univ, Munich, Germany
| | - S. Schmitz
- Haematology/Oncology Group Practice, Koblenz, Germany; Johannes Gutenberg-University, Mainz, Germany; Haematology/Oncology Group Practice, Leipzig, Germany; Haematology/Oncology Group Practice, Cologne, Germany; Ludwig-Maximilians Univ, Munich, Germany
| | - M. Unterhalt
- Haematology/Oncology Group Practice, Koblenz, Germany; Johannes Gutenberg-University, Mainz, Germany; Haematology/Oncology Group Practice, Leipzig, Germany; Haematology/Oncology Group Practice, Cologne, Germany; Ludwig-Maximilians Univ, Munich, Germany
| | - M. H. Dreyling
- Haematology/Oncology Group Practice, Koblenz, Germany; Johannes Gutenberg-University, Mainz, Germany; Haematology/Oncology Group Practice, Leipzig, Germany; Haematology/Oncology Group Practice, Cologne, Germany; Ludwig-Maximilians Univ, Munich, Germany
| | - W. Hiddemann
- Haematology/Oncology Group Practice, Koblenz, Germany; Johannes Gutenberg-University, Mainz, Germany; Haematology/Oncology Group Practice, Leipzig, Germany; Haematology/Oncology Group Practice, Cologne, Germany; Ludwig-Maximilians Univ, Munich, Germany
| |
Collapse
|
20
|
Hiddemann W, Forstpointner R, Dreyling M, Gramatzki M, Böck HP, Haenel M, Seymour JF, Unterhalt M. Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6527] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- W. Hiddemann
- Ludwig-Maximilians-Universitat, Muenchen, Germany; Friedrich Alexander Universität Erlangen, Erlangen, Germany; Practice of Hematology, Offenbach, Germany; Klin Chemnitz, Chemnitz, Germany; Peter Maccallum Cancer Institute, East Melbourne, Australia
| | - R. Forstpointner
- Ludwig-Maximilians-Universitat, Muenchen, Germany; Friedrich Alexander Universität Erlangen, Erlangen, Germany; Practice of Hematology, Offenbach, Germany; Klin Chemnitz, Chemnitz, Germany; Peter Maccallum Cancer Institute, East Melbourne, Australia
| | - M. Dreyling
- Ludwig-Maximilians-Universitat, Muenchen, Germany; Friedrich Alexander Universität Erlangen, Erlangen, Germany; Practice of Hematology, Offenbach, Germany; Klin Chemnitz, Chemnitz, Germany; Peter Maccallum Cancer Institute, East Melbourne, Australia
| | - M. Gramatzki
- Ludwig-Maximilians-Universitat, Muenchen, Germany; Friedrich Alexander Universität Erlangen, Erlangen, Germany; Practice of Hematology, Offenbach, Germany; Klin Chemnitz, Chemnitz, Germany; Peter Maccallum Cancer Institute, East Melbourne, Australia
| | - H.-P. Böck
- Ludwig-Maximilians-Universitat, Muenchen, Germany; Friedrich Alexander Universität Erlangen, Erlangen, Germany; Practice of Hematology, Offenbach, Germany; Klin Chemnitz, Chemnitz, Germany; Peter Maccallum Cancer Institute, East Melbourne, Australia
| | - M. Haenel
- Ludwig-Maximilians-Universitat, Muenchen, Germany; Friedrich Alexander Universität Erlangen, Erlangen, Germany; Practice of Hematology, Offenbach, Germany; Klin Chemnitz, Chemnitz, Germany; Peter Maccallum Cancer Institute, East Melbourne, Australia
| | - J. F. Seymour
- Ludwig-Maximilians-Universitat, Muenchen, Germany; Friedrich Alexander Universität Erlangen, Erlangen, Germany; Practice of Hematology, Offenbach, Germany; Klin Chemnitz, Chemnitz, Germany; Peter Maccallum Cancer Institute, East Melbourne, Australia
| | - M. Unterhalt
- Ludwig-Maximilians-Universitat, Muenchen, Germany; Friedrich Alexander Universität Erlangen, Erlangen, Germany; Practice of Hematology, Offenbach, Germany; Klin Chemnitz, Chemnitz, Germany; Peter Maccallum Cancer Institute, East Melbourne, Australia
| |
Collapse
|
21
|
Dreyling MH, Forstpointner R, Ludwig WD, Gramatzki M, Boeck HP, Haenel M, Wandt H, Parwaresch R, Unterhalt M, Hiddemann W. Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: Follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6528] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. H. Dreyling
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - R. Forstpointner
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - W.-D. Ludwig
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - M. Gramatzki
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - H.-P. Boeck
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - M. Haenel
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - H. Wandt
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - R. Parwaresch
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - M. Unterhalt
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| | - W. Hiddemann
- Univ Hosp Grosshadern/LMU, Munich, Germany; Robert Rössle Hospital/Charite, Berlin, Germany; Univ Hosp, Erlangen, Germany; Practice of Hematology-Oncology, Offenbach, Germany; Hosp Kuechwald, Chemnitz, Germany; Klin Nord, Nuernberg, Germany; Univ of Schleswig-Holstein, Kiel, Germany
| |
Collapse
|
22
|
Rohatiner AZS, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, Fisher RI, Unterhalt M, Arranz R, Chisesi T, Aviles A, Lister TA. Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma. J Clin Oncol 2005; 23:2215-23. [PMID: 15684317 DOI: 10.1200/jco.2005.06.146] [Citation(s) in RCA: 145] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To determine whether interferon (IFN) -α2, when given with or following chemotherapy, influences response rate, remission duration, and survival in newly diagnosed patients with follicular lymphoma. Patients and Methods Ten phase III studies evaluating the role of IFN-α2 in 1,922 newly diagnosed patients with follicular lymphoma were analyzed. Updated individual patient data were used to perform meta-analyses for response, survival, and remission duration. Results The addition of IFN-α2 to initial chemotherapy did not significantly influence response rate. An overall meta-analysis for survival showed a significant difference in favor of IFN-α2, but also showed significant heterogeneity between studies. Further analyses were carried out in order to explain this heterogeneity, and to define the circumstances in which IFN-α2 prolonged survival. The survival advantage was seen when IFN-α2 was given: (1) in conjunction with relatively intensive initial chemotherapy (2P = .00005), (2) at a dose ≥ 5 million units (2P = .000002), (3) at a cumulative dose ≥ 36 million units per month (2P = .000008), and (4) with chemotherapy rather than as maintenance therapy (P = .004). With regard to remission duration, there was also a significant difference in favor of IFN-α2, irrespective of the intensity of chemotherapy used, IFN dose, or whether IFN was given as a maintenance strategy or with chemotherapy. Conclusion When given in the context of relatively intensive initial chemotherapy, and at a dose ≥ 5 million units (≥ 36 × 106 units per month), IFN-α2 prolongs survival and remission duration in patients with follicular lymphoma.
Collapse
Affiliation(s)
- A Z S Rohatiner
- Department of Medical Oncology, St Bartholomew's Hospital, 45 Little Britain, London, EC1A 7BE, United Kingdom.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
In the last years monoclonal antibodies directed against B-cell associated epitopes have enriched our armentarium of therapeutic strategies against malignant B-cell lymphoma. Monoclonal antibodies are characterized by a different mode of action compared to chemotherapy, thereby opening new avenues in lymphoma treatment. These monoclonal antibodies can exert their anti-lymphoma activity directly by an intrinsic cytotoxic effect or indirectly as a carrier of cytotoxic drugs or radioisotopes. Rituximab, an anti-CD20 monoclonal antibody, was proven to be highly active in indolent as well as aggressive lymphoma, in particular when combined with chemotherapy. The anti-CD52 antibody alemtuzumab was shown to induce remissions in high risk CLL. Furthermore, clinical trials have demonstrated promising activity of monoclonal antibodies conjugated to radioisotopes such as the (131)iodine anti-CD20 antibody tositumomab or the (90)yttrium anti-CD20 antibody ibritumomab tiuxetan.
Collapse
Affiliation(s)
- C Buske
- Medizinische Klinik III, Klinikum Grosshadern der Ludwig Maximilians Universität München.
| | | | | | | |
Collapse
|
24
|
Abstract
Advanced stage mantle cell lymphoma (MCL) with a median survival of only three years and virtually no long-term survivors represents the lymphoma subtype with the poorest prognosis and remains incurable with conventional chemotherapy. Recently two randomized trials of the German Low Grade Lymphoma Study Group (GLSG) demonstrated the superiority of a combined immunochemotherapy with the anti-CD20 antibody rituximab in first-line therapy (R-CHOP) as well as in relapsed disease (R-FCM). In addition, in a trial of the European MCL Network, intensified-consolidation with high-dose radiochemotherapy followed by autologous stem cell transplantation significantly improved the progression-free survival in patients up to 65 years of age. However, the vast majority of patients with MCL will eventually relapse. Thus, new strategies such as allogenic transplantation after dose-reduced conditioning or novel molecular targeting agents (e. g. proteasome inhibitors or radiolabeled antibodies) are urgently warranted to further improve the long-term outcome of MCL.
Collapse
MESH Headings
- Age Factors
- Aged
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Combined Modality Therapy
- Cyclophosphamide/therapeutic use
- Disease-Free Survival
- Doxorubicin/therapeutic use
- Female
- Humans
- Immunotherapy
- Lymphoma, Mantle-Cell/drug therapy
- Lymphoma, Mantle-Cell/mortality
- Lymphoma, Mantle-Cell/radiotherapy
- Lymphoma, Mantle-Cell/therapy
- Male
- Middle Aged
- Prednisone/therapeutic use
- Prognosis
- Proteasome Inhibitors
- Radiotherapy Dosage
- Randomized Controlled Trials as Topic
- Recurrence
- Risk Factors
- Rituximab
- Stem Cell Transplantation
- Survival Analysis
- Time Factors
- Transplantation, Autologous
- Vincristine/therapeutic use
Collapse
Affiliation(s)
- G Lenz
- Medizinische Klinik III, Klinikum der Ludwig Maximilians-Universität, München.
| | | | | | | |
Collapse
|
25
|
Hiddemann W, Dreyling M, Unterhalt M, Repp R, Hermann S, Haenel A, Metzner B, Pott C, Hartmann F, Parwaresch R. Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - M. Dreyling
- Ludwig-Maximilians-University, München, Germany
| | | | - R. Repp
- Ludwig-Maximilians-University, München, Germany
| | - S. Hermann
- Ludwig-Maximilians-University, München, Germany
| | - A. Haenel
- Ludwig-Maximilians-University, München, Germany
| | - B. Metzner
- Ludwig-Maximilians-University, München, Germany
| | - C. Pott
- Ludwig-Maximilians-University, München, Germany
| | - F. Hartmann
- Ludwig-Maximilians-University, München, Germany
| | | |
Collapse
|
26
|
Forstpointner R, Hänel A, Repp R, Hermann S, Metzner B, Pott C, Hartmann F, Rothmann F, Böck HP, Wandt H, Unterhalt M, Hiddemann W. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group]. Dtsch Med Wochenschr 2002; 127:2253-8. [PMID: 12397539 DOI: 10.1055/s-2002-35017] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
BACKGROUND AND OBJECTIVE Rituximab has shown a high activity in relapsed follicular lymphomas when given alone. Further on, phase-II-studies indicate that its addition to chemotherapy may improve the response rate substantially. However, so far, prospective randomized studies have not been available. PATIENTS AND METHODS In 1998 the GLSG started a multicenter trial in patients with relapsed or refractory indolent lymphoma or mantle cell lymphoma. A fludarabine-containing regimen (FCM) was chosen for salvage therapy, with fludarabine 25 mg/m(2)/d 1-3, cyclophosphamide 200 mg/m(2) d 1-3 and mitoxantrone 8 mg/m(2) d 1. A total of four courses, every 4 weeks were given. Patients were prospectively randomized for FCM alone or the immunochemotherapy with R-FCM (375 mg/m(2) one day before FCM) RESULTS: About 147 randomized patients 93 had follicular, 40 mantle cell and 14 lymphoplasmocytic/-cytoid lymphoma. Statistical analysis was performed by sequential testing and indicated for 94 fully evaluable patients a significant advantage for the R-FCM-arm, with an overall response rate of 83 % as compared to 58%, when treated with FCM alone (CR: 35 % vs. 13 %). Similar improvements of remission rate were detected in the different lymphoma subgroups, especially in MCL (OR: 65 % vs. 33 %). Both treatment options were associated with hematological toxicities of grade III and IV, but well tolerated; infectious complications were rare, with no difference between the two treatment groups. CONCLUSION This prospectively randomized trial demonstrates for the first time a significant improvement of the combined immunochemotherapy related to the remission rate in patients with relapsed or refractory indolent lymphoma.
Collapse
MESH Headings
- Adult
- Aged
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antimetabolites/administration & dosage
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Combined Modality Therapy
- Female
- Humans
- Immunosuppressive Agents/administration & dosage
- Immunotherapy
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Lymphoma, Follicular/drug therapy
- Lymphoma, Mantle-Cell/drug therapy
- Lymphoma, Non-Hodgkin/drug therapy
- Male
- Middle Aged
- Mitoxantrone/administration & dosage
- Recurrence
- Remission Induction
- Retrospective Studies
- Rituximab
- Time Factors
- Vidarabine/administration & dosage
- Vidarabine/analogs & derivatives
Collapse
Affiliation(s)
- R Forstpointner
- Medizinische Klinik und Poliklinik III, Grosshadern, Klinikum der Universität München, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Hiddemann W, Dreyling M, Unterhalt M. Aktuelle Entwicklungen in der Therapie follikulärer Keimzentrumslymphome. Der Onkologe 2001. [DOI: 10.1007/s007610170045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Kern W, Schleyer E, Braess J, Wittmer E, Ohnesorge J, Unterhalt M, Wörmann B, Büchner T, Hiddemann W. Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias. Ann Hematol 2001; 80:334-9. [PMID: 11475146 DOI: 10.1007/s002770100293] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Patients with refractory acute leukemias after intensive induction and salvage attempts have a particularly poor prognosis and therapeutic options are limited. In the current study, the pharmacologically based FIS-HAM regimen was applied, which included fludarabine 15 mg/m2 q 12 h (days 1, 2, 8, and 9), cytosine arabinoside as a 45-min infusion every 3 h at 750 mg/m2 per single application (days 1, 2, 8, and 9), and mitoxantrone 10 mg/m2 (days 3, 4, 10, 11). Twenty-six intensively pretreated patients [median age: 38 years; range: 22-65; 16 cases of acute myeloid leukemia (AML) and 10 of acute lymphoblastic leukemia (ALL)] were included. Of 16 patients with AML, 5 achieved a complete remission (CR, 31%), 1 a partial remission (PR, 6%), 2 were nonresponders (13%), and 8 succumbed to early death (ED, 50%). Of 10 patients with ALL, 5 achieved a CR, 1 a PR, 1 was a nonresponder, and 3 died early. Overall, the CR rate was 38%. The median disease-free survival time was 50 days and median survival 90 days. Two patients underwent allogeneic bone marrow transplantation and are alive after 27 and 28 months. Neutropenia amounted to a median of 46 days. Toxicity WHO III/IV included infection (61%), diarrhea (48%), nausea/vomiting (43%), impairment of heart function (30%), and mucositis (26%). The current data indicate a significant activity of FIS-HAM chemotherapy in advanced acute leukemias. However, due to its pronounced toxicity, this regimen should be restricted to third-line therapy for patients expecting a suitable donor for allogeneic transplantation, and supportive treatment should be optimized.
Collapse
Affiliation(s)
- W Kern
- University Hospital Grosshadern, Department of Medicine III, Ludwig-Maximilians-University, Munich, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E, Trümper L, Brugger W, Ostermann H, Atzpodien J, Hallek M, Aulitzky E, Hiddemann W. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000; 79:493-500. [PMID: 11043420 DOI: 10.1007/s002770000163] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
PURPOSE The current study was initiated to assess the clinical efficacy and side effects of rituximab in patients with relapsed advanced stage follicular lymphoma. PATIENTS AND METHODS The study was performed as an open-label non-randomized multicenter phase-II trial and included patients older than 18 years of age with relapsed advanced-stage follicular lymphomas (FL) grades I and II, according to the REAL classification, or with centroblastic/centrocytic (CB/CC lymphomas according to the Kiel classification. Four weekly doses of 375 mg/m2 rituximab were applied. RESULTS 38 patients from eight centers were included between January 1997 and January 1998 and were evaluable for response and toxicity on an intention to treat basis. The median age was 55 years (range 26-75 years). Thirteen patients (35%) were in first relapse, 11 patients (30%) in second, and 13 patients (35%) in third relapse. The median time between primary diagnosis and study entry was 4.6 years (range 0.9-14.7 years). Twenty-three patients tolerated the application of rituximab without adverse events; in 13 cases the infusion rate had to be reduced because of side effects; in two patients the application was stopped because of pharyngeal edema and anaphylactoid reaction. The most frequent side effects were fever (13 patients) and rigor (13 patients); 65% of the side effects were observed after the first infusion. Twenty grade-III/IV side effects were considered to be related to treatment: lymphocytopenia (3), granalocytopenia (1), thrombocytopenia (2), fever (1), hyperglycermia (1), venous thrombosis (1), syncope (1), plasmatic coagulation disorder (1), shortness of breath (2), photosensitivity (1), cardiac failure (1), chills (1), sepsis (1), tumor lysis (1), anemia (1), and pharyngeal edema (1). Eight patients were not eligible for assessment of response because of non-follicular subtypes of low-grade lymphomas (n =6) or early termination of therapy at the first infusion because of severe side effects (n =2). From the 30 evaluable cases with follicular lymphomas, five patients achieved a complete remission (CR) (17%), nine patients a partial remission (PR) (30%), and two patients a minor response (MR) (7%). The overall response rate was 47%. The median time to treatment progression (TTP) was 201 days (range 64-293 days), with five patients experiencing long-lasting remissions of 214-293 days duration. In three patients, the rituximab-induced remission exceeded the preceding progression-free interval substantially. Bulky disease (P=0.058) and/or bone-mar row involvement (P=0.046) were associated with poor response. CONCLUSION This study confirms the moderate treatment-related toxicity and the high antilymphoma activity of rituximab in patients with relapsed follicular lymphoma. Further studies are needed to determine the role of rituximab in the first-line treatment of these disorders and its combination with conventional chemotherapy.
Collapse
Affiliation(s)
- M Feuring-Buske
- Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University of München, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Braess J, Wegendt C, Jahns-Streubel G, Kern W, Keye S, Unterhalt M, Schleyer E, Hiddemann W. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine. Br J Haematol 2000; 109:388-95. [PMID: 10848830 DOI: 10.1046/j.1365-2141.2000.02056.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
High-dose cytosine arabinoside (AraC)-containing regimens have shown the highest antileukaemic efficacy of all currently used regimens in the treatment of acute myeloid leukaemia (AML). This study aimed at increasing the antileukaemic potential of high-dose AraC by raising intracellular levels of AraC triphosphate (AraCTP), which is the mediator of cytotoxicity, via biochemical modulation by inhibitors of ribonucleotide reductase (RR) or haematopoietic growth factors (HGFs). Blasts from patients with de novo AML were analysed for their formation of AraCTP under high-dose AraC conditions (20 microM over 3 h) without prior modulation (n = 47) after a 2-h pre-exposure with fludarabine (50 microg/ml) (n = 40) or gemcitabine (30 ng/ml) (n = 40) and after a 48-h pre-exposure to granulocyte colony-stimulating-factor (G-CSF; 100 ng/ml) (n = 27) or granulocyte-macrophage colony-stimulating-factor (GM-CSF; 100 U/ml) (n = 28). Unmodulated formation of AraCTP (median 239.8 ng/107 cells) could not be increased via modulation by gemcitabine (232.4 ng/107 cells) or fludarabine (247.8 ng/107 cells). The lack of effect of RR inhibitors was also observed for all other known metabolites of AraC [Ara-cytosine monophosphate (CMP), Ara-cytosine diphosphate (CDP), AraCDP-choline, Ara-uridine monophosphate (UMP), Ara-uridine diphosphate (UDP) and Ara-uridine triphosphate (UTP)]. In contrast, pre-exposure to HGFs led to significant increases in AraCTP formation (G-CSF 556.0 ng/107 cells, 2.31-fold increase, P < 0.001; GM-CSF 447.9 ng/107 cells, 1.87-fold increase, P < 0.0001). To establish the mechanism responsible for these effects, the activity of the rate-limiting enzyme of AraC metabolism, deoxycytidine kinase (dCK), was investigated (n = 33). In vivo exposure to GM-CSF led to increases in dCK activity from unmodulated values at 0 h (29.8 pmol/min/mg protein) to 34.3 pmol/min/mg protein at 24 h (1.15-fold increase) and 54.5 pmol/min/mg protein at 48 h (1. 83-fold increase). The raise in dCK activity over 48 h was significant (P < 0.013).
Collapse
Affiliation(s)
- J Braess
- Medical Clinic III, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
Substantial advances in antigen-targeted lymphoma therapy have been achieved in recent years that make the use of monoclonal antibodies a highly attractive concept and promise further improvements in the clinical management of malignant lymphoma. The development of the chimeric anti-CD20 antibody IDEC-C2B8 (Rituximab) proved the concept of an effective therapy with a single unconjugated monoclonal antibody in lymphoma patients. Radioimmunoconjugates with myeloablative activity induced response rates of 80-100% in heavily pretreated patients. Progress in the genetic engineering of immunotoxins has improved the efficacy of these constructs. Ongoing prospective clinical trials will define the optimal use of these innovative therapeutic agents in patients with malignant lymphoma, and may establish therapeutic strategies with a high anti-lymphoma specificity and a low unspecific toxicity.
Collapse
Affiliation(s)
- M Feuring-Buske
- Medizinische Klinik III, Klinikum Grosshadern, Ludwig-Maximilians Universität, Munich, Germany.
| | | | | | | |
Collapse
|
32
|
Schleyer E, Rudolph KL, Braess J, Unterhalt M, Ehninger G, Hiddemann W, Kern W. Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. Cancer Chemother Pharmacol 2000; 45:165-71. [PMID: 10663632 DOI: 10.1007/s002800050025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE To detect possible interactions between (-)-formyl-tetrahydrofolic acid (leucovorin, (-)-fTHF) and (+)-formyl-tetrahydrofolic acid ((+)-fTHF) on the plasma and intracellular pharmacokinetics following their simultaneous administration. METHODS Plasma levels of (-)-fTHF, (-)-methyl-THF, and (+)-fTHF were determined in samples from four volunteers following the administration of both (-)-fTHF and (+/-)-fTHF and in seven patients during a 5-fluorouracil (5-FU)/fTHF combination chemotherapy. In addition, the intracellular uptake of (14)C-(-)-mTHF in the presence of (+)-mTHF at increasing concentrations was measured in vitro. Analyses were performed using a highly specific high-performance liquid chromatography procedure. RESULTS The pharmacokinetic parameters obtained for (-)-fTHF following the administration of (-)-fTHF only were: terminal half-life, 1.2 h; area under the curve, 10 microg. h/ml; maximum concentration, 12 microg/ml; clearance, 305 ml/min; volume of distribution, 19 l. The parameters did not differ significantly as compared with those obtained following the administration of (+/-)-fTHF to both volunteers and patients. There were no differences in the pharmacokinetics of (-)-mTHF or in the protein binding of both substances with the different forms of administration. The intracellular uptake of (14)C-(-)-mTHF did not depend on the presence of (+)-mTHF at either concentration. CONCLUSIONS These data suggest that (-)-fTHF is not therapeutically superior to (+/-)-fTHF and that the latter is appropriate during combination chemotherapy with 5-FU/fTHF in patients with colorectal cancers.
Collapse
Affiliation(s)
- E Schleyer
- Carl-Gustav-Carus-University, Department of Internal Medicine I, Dresden, Germany
| | | | | | | | | | | | | |
Collapse
|
33
|
Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wörmann B, Büchner T, Hiddemann W. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 2000; 14:226-31. [PMID: 10673737 DOI: 10.1038/sj.leu.2401668] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
To improve the basis for the stratification of patients with refractory and relapsed acute myeloid leukemia (AML) univariate and multivariate analyses of prognostic factors were performed in 254 patients (median age 50 years, range 18-74) undergoing S-HAM salvage chemotherapy during two consecutive prospective trials of the German AML Cooperative Group. In a multivariate analysis, duration of the first complete remission (CR) was the only factor associated with time to treatment failure (P = 0.0223). Disease-free survival was influenced by a short duration of the first CR of less than 6 months (P = 0.0001), WBC (P = 0.0018), blast count (P = 0.0037), and neutrophil count (P = 0.0119). The achievement of CR was related to the hemoglobin level only (P = 0.0457), the early death rate was related to age only (P = 0.0109), and survival was related to the bilirubin level only (P = 0.0166). In the subgroup of 104 patients in whom additional karyotype analyses were performed prior to first-line therapy unfavorable chromosome abnormalities were associated with a lower CR rate (univariate analysis, P = 0.0342; CR 24% vs 53%) and were the only factor related to survival. These analyses warrant the further evaluation of the impact of cytogenetic abnormalities on the outcome of patients with advanced AML in order to improve the characterization according to duration of first CR and to WBC of distinct subgroups of patients with differing prognoses as a basis for stratification in future trials.
Collapse
Affiliation(s)
- W Kern
- University Hospital Grosshadern, Department of Medicine III, Ludwig-Maximilians-University, München, Germany
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Wulf GG, Unterhalt M, Buchwald A, Zenker D, Kreuzer H, Hiddemann W. Hypercoagulability in a patient with hypodysfibrinogenemia: implications for clinical management. Acta Haematol 1999; 101:209-12. [PMID: 10436304 DOI: 10.1159/000040956] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Dysfibrinogenemia accounts for approximately 0.7% of thrombophilia in patients with venous thromboembolic disease. In 20% of these patients, plasma thrombophilic dysfibrinogen is below 1.0 mg/ml, defining hypodysfibrinogenemia. We describe a young female patient, in whom hypodysfibrinogenemia was the cause of several severe thromboembolic events which occurred even under oral anticoagulation monitored by a standard prothrombin time (PT) test. In this patient, the standard PT test according to Quick underestimated the plasma coagulability in vivo, presumably due to the low levels of dysfunctional fibrinogen as the substrate of the thromboplastin reagent. A PT test supplemented with bovine plasma fibrinogen (Thrombotest) revealed lower fibrinogen-independent international normalized ratio (INR) values in the proposita on oral anticoagulation compared to a control group with eufibrinogenemia. Monitoring therapy with the fibrinogen-independent Thrombotest secured safe anticoagulation in this patient. We suggest to consider PT tests with exogenous fibrinogen (e.g. Thrombotest) to monitor oral anticoagulation in the rare thrombophilic patients with hypodysfibrinogenemia.
Collapse
Affiliation(s)
- G G Wulf
- Department of Hematology and Oncology, University of Göttingen, Göttingen, Germany.
| | | | | | | | | | | |
Collapse
|
35
|
Buske C, Feuring-Buske M, Unterhalt M, Hiddemann W. [New developments in therapy of non-Hodgkin lymphomas with monoclonal antibodies]. Dtsch Med Wochenschr 1999; 124:842-7. [PMID: 10432945 DOI: 10.1055/s-2007-1024429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- C Buske
- Medizinische Klinik III, Klinikum Grosshadern, Ludwig-Maximilians-Universität München.
| | | | | | | |
Collapse
|
36
|
Buske C, Feuring-Buske M, Unterhalt M, Hiddemann W. Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy. Eur J Cancer 1999; 35:549-57. [PMID: 10492626 DOI: 10.1016/s0959-8049(98)00420-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Although much progress has been made in the understanding of the pathobiology of malignant lymphomas in recent years, progress in the treatment of patients with this diagnosis has been limited. Monoclonal antibody therapy is an innovative and promising concept in the treatment of malignant lymphoma, and the current status of this treatment is reviewed here. Phase I/II clinical trials have proven the high antilymphoma activity of antibody-based therapeutic strategies. Radioimmunoconjugates with myeloablative activity have induced response rates of between 80 and 100% in heavily pretreated patients. The chimeric monoclonal antibody IDEC-C2B8 has shown high antilymphoma activity in patients with relapsed follicular lymphoma with an overall response rate of up to 50%. The combination of the IDEC-C2B8 antibody with standard chemotherapy has shown encouraging results with no increase in toxicity compared with chemotherapy alone. The introduction of antibody therapy promises to open new perspectives in the treatment of patients with malignant lymphoma. Prospective randomised clinical trials will define the patient who will gain maximal benefit from antibody-based therapy.
Collapse
Affiliation(s)
- C Buske
- Department of Internal Medicine III, Ludwig-Maximilians, University of Munich, Germany.
| | | | | | | |
Collapse
|
37
|
Krauss T, Augustin HG, Osmers R, Meden H, Unterhalt M, Kuhn W. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998; 92:457-60. [PMID: 9721789 DOI: 10.1016/s0029-7844(98)00208-7] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE Hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome is characterized by a distinct activation of the coagulation system. A mutation of the gene coding for coagulation Factor V (Factor V Leiden) has been identified as the most frequent risk factor for thrombosis. To identify risk factors for HELLP syndrome, we determined coagulation parameters and the Factor V Leiden mutation in women who previously had developed HELLP syndrome. METHODS Coagulation parameters (activated protein C resistance, antithrombin, protein C, protein S) were determined in 21 women 6 months to 9 years after they had developed HELLP syndrome in the third trimester. In addition, these women were analyzed for the presence of the Factor V Leiden mutation. RESULTS Of these analyzed women, 33% (seven of 21) had an activated protein C resistance (activated protein C ratio less than 2.0). Another 38% of the women had subnormal activated protein C ratios (2.0-2.3). Only 57% of the women with an activated protein C resistance were identified as heterozygous carriers of the Factor V Leiden mutation (four of seven). CONCLUSION Women with HELLP syndrome have a higher incidence of Factor V Leiden mutations. This increased incidence does not, however, account fully for the increased frequency of activated protein C resistance in these patients.
Collapse
Affiliation(s)
- T Krauss
- Department of Gynecology and Obstetrics, University of Göttingen, Germany.
| | | | | | | | | | | |
Collapse
|
38
|
Hiddemann W, Griesinger F, Unterhalt M. Interferon alfa for the treatment of follicular lymphomas. Cancer J Sci Am 1998; 4 Suppl 2:S13-8. [PMID: 9672770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
PURPOSE Recombinant human interferon alfa (rIFN-alpha) has demonstrated significant activity against follicular lymphomas when applied as salvage treatment after the failure of conventional therapy. It has also been shown to exhibit synergistic antitumor activity when given simultaneously with certain cytostatic agents. PATIENTS AND METHODS Against this background, two major strategies were followed to incorporate rIFN-alpha into the first-line treatment of follicular lymphomas: application simultaneously with initial cytotoxic chemotherapy and application as maintenance treatment after successful initial chemotherapy. RESULTS Of the five prospective randomized trials performed to assess the activity of rIFN-alpha in combination with initial chemotherapy versus the activity of chemotherapy alone, three studies showed that rIFN-alpha plus chemotherapy yielded no beneficial effect on remission rate, remission duration, or overall survival. In all three of these trials, chemotherapy consisted of a single alkylating agent. In contrast, a significant improvement in remission rate and remission duration was observed in two studies when rIFN-alpha was combined with anthracycline-containing regimens. Five prospective randomized studies have evaluated the role of rIFN-alpha as maintenance therapy after successful cytoreductive chemotherapy. Four of these studies have either found no significant prolongation of the disease-free interval or shown significant improvement in disease-free survival only in patients achieving a complete remission with initial cytoreductive treatment. In all four studies, relatively low doses of rIFN-alpha were administered for a limited time. A different outcome emerged in the fifth study, by the German Low Grade Lymphoma Study Group, in which patients received higher doses of rIFN-alpha with no restriction on duration of therapy. Patients treated with rIFN-alpha had a significantly prolonged median progression-free interval (30 versus 19 months), and at 4 years, 45% of patients receiving rIFN-alpha maintenance therapy remained relapse-free, compared with 26% of patients in the untreated control group (P = 0.003). CONCLUSION Collectively, these data demonstrate that rIFN-alpha adds substantially to the treatment of follicular lymphomas either when combined with anthracycline-containing cytoreductive chemotherapy or when given as long-term maintenance therapy.
Collapse
Affiliation(s)
- W Hiddemann
- Department of Hematology and Oncology, University of Göttingen, Germany
| | | | | |
Collapse
|
39
|
Hiddemann W, Unterhalt M, Herrmann R, Wöltjen HH, Kreuser ED, Trümper L, Reuss-Borst M, Terhardt-Kasten E, Busch M, Neubauer A, Kaiser U, Hanrath RD, Middeke H, Helm G, Freund M, Stein H, Tiemann M, Parwaresch R. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998; 16:1922-30. [PMID: 9586911 DOI: 10.1200/jco.1998.16.5.1922] [Citation(s) in RCA: 90] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To compare mantle-cell lymphomas (MCLs) and follicle-center lymphomas (FCLs) for their features of clinical presentation, response to chemotherapy, and prognosis on the basis of a prospective randomized clinical trial. PATIENTS AND METHODS Patients with MCL and FCL who entered onto the prospective randomized comparison of cyclophosphamide, vincristine, and prednisone (COP) versus prednimustine and mitoxantrone (PmM) followed by a second randomization for interferon (IFN) maintenance versus observation only. RESULTS One hundred sixty-five of 234 patients had FCL and 45 of 234 patients had MCL. With FCL, both sexes were equally affected (men, 47%); patients with MCL were predominantly men (78%; P < .0004) and had a higher median age (64 v 53 years; P < .0001). Patients with MCL also had more widespread disease, reflected by the proportion of patients with two or greater extranodal manifestations (43% v 21%; P < .005) and nine or greater involved nodal areas (64% v 45%; nonsignificant [NS]). Response to chemotherapy was significantly lower in patients with MCL (complete remission [CR] + partial remission [PR], 69% v 88%; P < .05) and occurred at a slower pace. Patients with MCL also had a shorter event-free interval (median, 8 v 24 months; P < .0001) and overall survival (median, 28 v 77 months; P < .0001). In both subtypes, however, patients with less than two residual lymphoma manifestations in remission experienced a relatively good prognosis with an estimated 5-year survival of greater than 60% for MCL and greater than 75% for FCL. CONCLUSION MCL and FCL differ substantially in their features of presentation, response to chemotherapy, and long-term prognosis. The extent of residual disease after completion of chemotherapy discriminates patients with different prognosis and may be used for the stratification of postremission strategies.
Collapse
Affiliation(s)
- W Hiddemann
- Department of Hematology and Oncology, University of Göttingen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Binder L, Schiel X, Binder C, Menke CF, Schüttrumpf S, Armstrong VW, Unterhalt M, Erichsen N, Hiddemann W, Oellerich M. Clinical outcome and economic impact of aminoglycoside peak concentrations in febrile immunocompromised patients with hematologic malignancies. Clin Chem 1998; 44:408-14. [PMID: 9474052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The aim of this study was to investigate the clinical and economic significance of aminoglycoside peak concentrations in febrile neutropenic patients with hematologic malignancies. Sixty-one patients were treated according to protocol II of the Paul-Ehrlich-Gesellschaft: initial application of gentamicin or tobramycin in combination with a cephalosporin or ureidopenicillin and, after 3 days, a potential change of antibiosis to be decided in case of nonresponse. At the same time, samples were collected by an independent controller. We found a significant dependence of clinical outcome on aminoglycoside peak concentrations (P = 0.004). Twelve of 17 patients with peak concentrations > 4.8 mg/L, but only 13 of 44 patients with concentrations < or = 4.8 mg/L, responded to initial therapy. Average infection-related costs per patient with peak values > 4.8 mg/L were US$1429, $1790, and $1701 for nursing, diagnostics, and therapeutics, respectively (total $4920). Expenses for patients with peak concentrations < or = 4.8 mg/L were approximately 1.8-fold higher (average total $8718). If all 61 patients had achieved peaks > 4.8 mg/L, the potential savings would have totalled $167,112. We conclude that neutropenic patients form a target group for successful pharmacokinetic intervention and cost saving.
Collapse
Affiliation(s)
- L Binder
- Department of Clinical Chemistry, Georg-August-Universitaet Goettingen, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Schleyer E, Kühn S, Rührs H, Unterhalt M, Kaufmann CC, Kern W, Braess J, Sträubel G, Hiddemann W. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Leukemia 1997; 11 Suppl 5:S15-21. [PMID: 9436933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Idarubicin is the first anthracycline that can be successfully administered via the oral route and thus may facilitate antineoplastic chemotherapy in an improved quality of life. These perspectives are somewhat hampered by the large variation in bioavailability between individual patients and the obvious requirement to monitor plasma concentration and area-under-the-curve values (AUC) for an appropriate adjustment of idarubicin dose. In this study we describe the pharmacokinetics of idarubicin and its main metabolite idarubicinol in 12 patients after oral application of 20 mg/m2 idarubicin on 3 consecutive days and demonstrate that the 24 h trough levels show a high correlation with AUC and may thus allow a rapid and easy determination of individual drug concentrations and an appropriate dose adjustment. The average terminal half-life was 30.5 h for idarubicin and 66.9 h for idarubicinol. The AUC for idarubicin and its main metabolite idarubicinol revealed a substantial interpatient variation with AUC values ranging from 25.7 to 114 ng x h/ml (average 58.1 ng x h/ml) for idarubicin and from 109.4-445.2 ng x h/ml (average 287.3 ng x h/ml) for idarubicinol. However, the ratio of idarubicin/idarubicinol differed only two folds from 1:3.7 to 1:7.7 with an average of 1:5.1. Both idarubicin and idarubicinol concentrations were highly reproducible, however, upon measurements after repeated applications within individual patients. Moreover, idarubicinol and idarubicin AUCs showed a good correlation with r = 0.78, indicating that the interindividual variation of idarubicin AUC reflects differences in absorption rather than in metabolism. In order to describe the interindividual bioavailability of idarubicin - represented by the respective AUC - measurement of a single data point with a high correlation with the AUC would be ideal. Our study demonstrates that the 24 h trough level shows such an excellent correlation (r = 0.96) with AUC, making it the perfect candidate for fast estimates of the individual bioavailability in a given patient. On this basis, the longitudinal measurement of the 24 h trough level may allow assessment of the impact of interindividual variations in AUC on clinical outcome and toxicity.
Collapse
MESH Headings
- Administration, Oral
- Adult
- Antibiotics, Antineoplastic/administration & dosage
- Antibiotics, Antineoplastic/pharmacokinetics
- Antibiotics, Antineoplastic/therapeutic use
- Antineoplastic Agents/blood
- Chromatography, High Pressure Liquid
- Daunorubicin/analogs & derivatives
- Daunorubicin/blood
- Half-Life
- Humans
- Idarubicin/administration & dosage
- Idarubicin/pharmacokinetics
- Idarubicin/therapeutic use
- Leukemia, Myeloid, Acute/blood
- Leukemia, Myeloid, Acute/drug therapy
- Lymphoma, Non-Hodgkin/blood
- Lymphoma, Non-Hodgkin/drug therapy
- Metabolic Clearance Rate
- Middle Aged
- Regression Analysis
Collapse
Affiliation(s)
- E Schleyer
- Department of Haematology and Oncology, University of Göttingen, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Hiddemann W, Unterhalt M, Buske C, Sack H. Treatment of follicular follicle centre lymphomas: current status and future perspectives. J Intern Med Suppl 1997; 740:55-62. [PMID: 9350184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Follicle centre lymphomas (FCLs) comprise the predominant subtype of indolent nodal lymphomas. Therapy is based on the stage of the disease and consists of extended field or total nodal irradiation in stages I and II. Patients with advanced stages III and IV may initially remain untreated and be watched until the occurrence of disease-related symptoms such as B-symptoms, haematopoietic insufficiency, lymphoma progression or bulky disease. On the occurrence of these signs a cytoreductive chemotherapy of mild to moderate intensity such as cyclophosphamide, vincristine, prednisone (COP) or mitoxantrone, chlorambucil, prednisone (MCP) should be initiated. In responding cases maintenance with interferon-alpha (IFN alpha) leads to a significant prolongation of the progression-free interval. Modifications of this approach include the upfront combination of IFN alpha with anthracycline containing combinations such as cyclophosphamide, doxorubicin, teniposide, prednisone (CHVP). New perspectives arise from the introduction of myelo-ablative radio-chemotherapy with subsequent stem-cell transplantation and antibody-based immunobiological therapies.
Collapse
Affiliation(s)
- W Hiddemann
- Abteilung Hämatologie und Onkologie, Universität Göttingen, Germany
| | | | | | | |
Collapse
|
43
|
Jahns-Streubel G, Reuter C, Auf der Landwehr U, Unterhalt M, Schleyer E, Wörmann B, Büchner T, Hiddemann W. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood 1997; 90:1968-76. [PMID: 9292531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The present study was undertaken to assess the predictive value of pretherapeutic determinants of ara-C metabolism and proliferative activity of leukemic blasts for early response to antileukemic therapy in the setting of granulocyte-macrophage colony-stimulating factor (GM-CSF)-based priming before and during TAD-9 induction in 36 consecutive patients with de novo acute myeloid leukemia (AML). Ara-C metabolism was assessed by the activities of deoxycytidine kinase (DCK), deoxycytidine deaminase (DCD), DNA polymerase alpha (Poly alpha), and overall polymerase (overall Poly). The fraction of cells in S phase (%S phase) and thymidine kinase (TK) activity were determined as a measure of proliferative activity. Early response to therapy was defined by the percentage of leukemic blasts in the bone marrow 5 to 7 days after completion of TAD-9 with less than 5% signaling an adequate response and greater than 5% indicating an inadequate early reduction, respectively. While neither %S phase, DCK, nor overall Poly activity were predictive for early response, TK and Poly alpha activities were significantly higher for cases with adequate blast cell clearance. The respective median values were for TK 3.8 versus 1.85 pmol/min/mg protein (P = .012), and for Poly alpha 1.9 versus 0.69 pmol/min/mg protein (P = .014). An inverse relation was detected for DCD activity which was significantly lower in responding patients with a median of 0.33 nmol/min/mg protein (range, 0.0 to 29.5) as compared to a median of 5.1 nmol/min/mg protein (range, 0.11 to 8.45) in early nonresponders, (P = .009). Taking the respective median values as arbitrary cut-points for high or low enzyme activities, responders and nonresponders could be discriminated prospectively. Hence, 14 of 16 cases (88%) with DCD activities below the median of 1.56 nmol/min/mg protein responded as compared to only 3 of 14 (22%) patients with higher DCD activities (P = .0004). From the 15 patients with TK activity above the overall median of 3.2 pmol/min/mg protein, 11 cases (73%) achieved an adequate blast cell clearance while only 6 of 17 cases (35%) with lower values responded (P = .035). Similarly, 12 of 15 patients (80%) with high Poly alpha levels (>1.22 pmol/min/mg protein) responded to induction therapy as compared to only 5 of 14 patients (36%) with lower enzyme activities (P = .02). By logistic regression analysis of enzyme activities, DCD activity was found to be the most sensitive parameter to predict an adequate blast cell clearance (P = .032). Activities of DCD and TK were not only associated with initial response but were also found predictive for remission duration. Hence, from 11 patients with low TK levels 8 (73%) relapsed within 1 year, whereas only 2 of 11 (18%) patients with high TK activity experienced a recurrence of their disease (P = .015). Six of 9 (66%) patients with higher than median DCD levels relapsed within 1 year, whereas 10 of 14 patients (71%) with lower DCD levels had a longer remission duration (P = .085). Analysis of DCD gene expression at the mRNA level by a semi-quantitative reverse transcriptase-polymerase chain reaction method showed that a high transcription rate of the DCD gene was associated with high enzyme activities and vice versa. Hence, the observed intraindividual differences in DCD activity are a reflection of differences in gene activity and transcription rate rather than of variants in translation. Although further analyses are needed to elucidate the molecular mechanisms that determine the variation of enzyme activities in individual patients, the present study strongly suggests that pretherapeutic determination of TK and Poly alpha as well as of DCD allows to predict response to TAD-9 + GM-CSF induction therapy and may provide the means for the development of a risk adapted treatment strategy.
Collapse
Affiliation(s)
- G Jahns-Streubel
- Department of Hematology and Oncology, Georg-August-University, Göttingen, Germany
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Hiddemann W, Unterhalt M, Sack H. [Current status of therapy of follicular germ center lymphoma and mantel cell lymphoma]. Internist (Berl) 1997; 38:122-34. [PMID: 9157057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- W Hiddemann
- Abteilung Hämatologie und Onkologie, Georg August Universität Göttingen
| | | | | |
Collapse
|
45
|
Kern W, Schleyer E, Unterhalt M, Wörmann B, Büchner T, Hiddemann W. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer 1997; 79:59-68. [PMID: 8988727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND The current study was initiated to assess the efficacy and side effects of a timed sequential application of high dose cytosine arabinoside (AraC) in combination with mitoxantrone (S-HAM) in patients with refractory acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). METHODS Patients with refractory AML or ALL were eligible for S-HAM salvage therapy, which was comprised of AraC, 1 g/m2 or 3 g/m2 every 12 hours, on Days 1, 2, 8, and 9 and mitoxantrone, 10 mg/m2/day, given on Days 3, 4, 10, and 11. RESULTS Of 22 fully evaluable patients, 14 patients (64%) achieved a complete remission whereas 5 patients (23%) succumbed to early death and 3 patients (14%) did not respond. Blood counts recovered at a median of 33.5 days after the start of treatment and complete remission was achieved after a median of 38 days. The median duration of complete remission was 4 months (range, 1-14 months) whereas overall survival time lasted for a median of 4.5 months (range, 1-30+ months). Treatment-associated toxicity was comprised predominantly of infection and diarrhea that reached World Health Organization Grades 3 and 4 in 64% and 32% of patients, respectively. Complementary pharmacokinetic evaluations of plasma AraC and AraU levels revealed no impact of initial AraC administration on the pharmacokinetics of subsequent AraC administrations and failed to demonstrate any evidence of self-potentiation. CONCLUSIONS The clinical data show the S-HAM regimen to be a promising approach for the treatment of patients with advanced acute leukemias. However, further evaluation at earlier stages of treatment is needed.
Collapse
Affiliation(s)
- W Kern
- Georg-August-University, Department of Hematology and Oncology, Göttingen, Germany
| | | | | | | | | | | |
Collapse
|
46
|
Braess J, Kern W, Unterhalt M, Kaufmann CC, Ramsauer B, Schüssler M, Kaeser-Fröhlich A, Hiddemann W, Schleyer E. Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone. Ann Hematol 1996; 73:201-4. [PMID: 8890711 DOI: 10.1007/s002770050229] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Cytarabine ocfosfate (YNK01) is a novel orally applicable prodrug of cytosine arabinoside. Recent pharmacokinetic studies have revealed a prolonged release of the cytotoxic agent cytosine arabinoside (araC) from hepatocytes into the systemic circulation, resulting in a half-life of approximately 24 h for araC. The specific pharmacokinetic characteristics of cytarabine ocfosfate lead to a prolonged exposure of leukemic cells to this antineoplasstic agent during the 14-day cycle. the oral applicability during outpatient treatment and the sustained antineoplastic activity of araC against slowly proliferating leukemic B-cells suggest that cytarabine ocfosfate might be a useful drug in the treatment of chronic lymphocytic leukemia. Four years after diagnosis of B-CLL, a 50-year-old patient was started on cytarabine ocfosfate. Sequentially, the patient's disease had proved refractory to treatment with chlorambucil/prednisone (31 months), fludarabine (5 months), and prednimustine/mitoxantrone (3 months). These established regimens were discontinued because of increasing lymphocytosis, significant thrombocytopenia, and progressive B-symptoms. Following three cycles of cytarabine ocfosfate B-symptoms resolved, lymphadenopathy disappeared, and thrombocytopenia was significantly reduced. The patient has been free of these symptoms on a dosage of 1500 mg cytarabine ocfosfate/day (cycle of 14 days with intervals of 14-21 days) for 24 months and remains in an ongoing partial remission.
Collapse
Affiliation(s)
- J Braess
- Department of Internal Medicine, University of Göttingen, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Hiddemann W, Schleyer E, Unterhalt M, Kern W, Büchner T. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells. Ther Drug Monit 1996; 18:341-9. [PMID: 8857548 DOI: 10.1097/00007691-199608000-00005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The increasing insights into the pharmacokinetics and the metabolism of arabinoside C (AraC) have improved the rationale for its application in leukemia therapy and have led to a pharmacologically directed design of antileukemic treatment. The current study aims at adding to this approach by detecting differences in the intracellular metabolism of AraC 5'-triphosphate (AraCTP) between leukemic and normal mononuclear blood cells. Measurements of intracellular AraCTP levels were complemented by determinations of plasma AraC and arabinoside uridine (AraU) concentrations and were performed in 26 patients with acute myeloid leukemia (AML) who were undergoing combination therapy, including high-dose (1.0 or 3.0 g/m2 x 2/day) AraC. Plasma AraC concentrations showed a linear relationship to the applied AraC dose but did not correlate with intracellular AraCTP levels. Substantial differences in AraCTP retention times were revealed, during 3-h infusions of either 1.0 or 3.0 g/m2 AraC in leukemic blasts from 10 patients with t1/2 values of 1.60-7.63 h (median, 2.42 h). In addition, AraCTP levels declined in only one patient by > 10% within the first hour after the end of therapy and remained constant or even increased up to 1.5-fold during a posttreatment period of 1-2.5 h in the other nine cases. In contrast, AraCTP retention times were relatively uniform in normal mononuclear blood cells from 11 patients, with t1/2 values of 3.34-5.29 h (median, 3.85 h). More importantly, AraCTP levels dropped by > 10% within the first hour after the end of the high-dose AraC infusion in eight of 11 cases. A posttherapeutic increase of > 10% was not observed in any patient. These differences in AraCTP pharmacokinetics between leukemic and normal blood cells provided the basis for a modified timing of AraC administration with the aim of selectively maintaining cytotoxic AraCTP levels in leukemic blasts while allowing an intermittent drop of AraCTP levels in normal cells. This modification may result in higher antileukemic activity without increasing the damaging effect on normal cells and may, thus, improve the therapeutic index for AraC.
Collapse
Affiliation(s)
- W Hiddemann
- Department of Hematology, University of Göttingen, Germany
| | | | | | | | | |
Collapse
|
48
|
Gahn B, Haase D, Unterhalt M, Drescher M, Schoch C, Fonatsch C, Terstappen LW, Hiddemann W, Büchner T, Bennett JM, Wörmann B. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia 1996; 10:946-51. [PMID: 8667650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Dysplastic hematopoiesis is the morphological hallmark of myelodysplastic syndromes. Dysplastic features in one or more lineages are also found frequently in bone marrow aspirates from patients with de novo AML and have been associated with an unfavorable prognosis. We asked whether dyshematopoiesis is an independent prognostic factor or an indicator of unrecognized secondary leukemia, identified by characteristic chromosomal abnormalities. Bone marrow aspirates from 102 patients with newly diagnosed AML were analyzed. Morphological analysis was obtained in all patients, flow cytometric analysis in 96 and successful cytogenetic analysis in 65 bone marrow aspirates. Dysgranulopoiesis (DysG) was found in 55, dysmegakaryopoiesis (DysM) in 32 and dyserythropoiesis (DysE) in 23 patients. Decreased side scatter signals of neutrophils in the flow cytometric analysis (DysS) were detected in 32 patients. DysG and DysS showed a highly significant correlation (P = 0.0005). DysG was an adverse negative prognostic factor for remission rate and event-free survival (P = 0.04, P = 0.02). An unfavorable karyotype was associated with a significantly lower chance for event-free survival (P = 0.002). The incidence of an unfavorable karyotype was significantly higher in patients with DysG (P = 0.01), DysM (P = 0.02) and DysS (P = 0.01). In patients with an unfavorable karyotype, dysplasia had no additional prognostic influence, however, in patients with a normal, favorable or prognostically uncertain karyotype DysG remained a predictor of lower remission rate (P = 0.03). We conclude that dysgranulopoiesis, dysmegakaryopoiesis and decreased side scatter signals of neutrophils are indicators of secondary leukemias in bone marrow aspirates from patients with de novo AML.
Collapse
Affiliation(s)
- B Gahn
- Department of Internal Medicine, Georg-August-University, Göttingen, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Unterhalt M, Herrmann R, Tiemann M, Parwaresch R, Stein H, Trümper L, Nahler M, Reuss-Borst M, Tirier C, Neubauer A, Freund M, Kreuser ED, Dietzfelbinger H, Bodenstein H, Engert A, Stauder R, Eimermacher H, Landys K, Hiddemann W. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia 1996; 10:836-43. [PMID: 8656680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The current study was initiated to compare the anti-lymphoma activity and side-effects of prednimustine/mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) in patients with advanced low-grade non-Hodgkin's lymphomas in way of a prospective randomized multicenter trial. Two hundred and forty-six patients with stage III or IV centroblastic-centrocytic (CB-CC (Kiel-classification)) or follicle center lymphoma (FCL (REAL classification)) and centrocytic (CC) or mantle-cell-lymphoma (MCL) were randomized for therapy with either PmM or COP and are fully evaluable for response and toxicity. PmM consisted of prednimustine 100 mg/m2/day on days 1-5 and mitoxantrone 8 mg/m2 /day days 1 and 2, while COP comprised cyclophosphamide 400 mg/m2/day on days 1-5, vincristine 1.4 mg/m2/day on day 1 and prednisone 100 mg/m2/day on days 1-5. Both regimens were repeated for a total of six cycles followed by an additional two courses for consolidation in responding cases and a subsequent second randomization for interferon alpha maintenance vs observation only. Overall response rates were comparable with 83% complete and partial remissions after COP and 84% remissions after PmM. PmM revealed a significantly higher rate of complete remissions (36 vs 18%, P < 0.006), the majority being achieved after four courses. The more rapid and possibly also more effective reduction of the lymphoma cell mass by PmM resulted in a tendency to a longer event-free interval for patients achieving remissions after PmM as compared to COP with estimated median event-free intervals of 31 vs 14 months, respectively (P=0.04). Separate analysis of lymphoma subtypes showed a tendency to a lower rate of complete remission in CC or MCL as compared to CB-CC or FCL (16 vs 30%, P=0.12, NS) while overall response rates were in a similar range (81 vs 85%). In both subtypes, PmM induced a higher rate of complete remission while overall response rates were comparable after PmM or COP. Treatment associated side-effects comprised predominantly myelosuppression and granulocytopenia in particular which was more frequently observed after PmM than COP (43 vs 31 %, P < 0.0001). This difference was clinically irrelevant, however, since serious infectious complications were encountered in less than 3% of cycles after both regimens. COP therapy was associated with a significantly higher incidence and degree of hair loss and complete alopecia (31 vs 2%) as well as of peripheral neurotoxicity (23 vs 2%). These data show that both PmM and COP reveal a high anti-lymphoma activity in patients with advanced stage non-Hodgkin's lymphoma. PmM appears advantageous with a higher rate of complete remissions and a better tolerability with regard to secondary side-effects. A longer follow-up is needed to assess the long-term effects of initial treatment on disease-free and overall survival and the impact on additional maintenance therapy with interferon alpha.
Collapse
Affiliation(s)
- M Unterhalt
- Dept of Hematology and Oncology, University of Göttingen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Schleyer E, Kühn S, Rührs H, Unterhalt M, Kaufmann CC, Kern W, Braess J, Sträubel G, Hiddemann W. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Leukemia 1996; 10:707-12. [PMID: 8618451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Idarubicin is the first anthracycline that can be successfully administered via the oral route and thus may facilitate antineoplastic chemotherapy at an improved quality of life. These perspectives are somewhat hampered by the large variation in bioavailability between individual patients and the obvious requirement to monitor plasma concentration and area-under the curve values (AUC) for an appropriate adjustment of idarubicin dose. In this study we describe the pharmacokinetics of idarubicin and its main metabolite idarubicin in 12 patients after oral application of 20 mg/m2 idarubicin on 3 consecutive days and demonstrate that the 24-h trough levels shows high correlation with AUC and may thus allow a rapid and easy determination of individual drug concentrations and an appropriate dose adjustment. The average terminal half-life was 30.5h for idarubicin and 66.9 h for idarubicinol. The AUC for idarubicin and its main metabolite idarubicinol revealed a substantial interpatient variation with AUC values ranging from 25.7 to 114 ng x h/ml (average 58.1 ng x h/ml) for idarubicin and from 109.4 - 445.2 ng x h/ml (average 287.3 ng x h/ml) for idarubicinol. However, the ratio of idarubicin/idarubicinol differed only two-fold from 1:3.7 to 1:7.7 with an average of 1:5.1. Both idarubicin and idarubicinol concentrations were highly reproducible, however, upon measurements after repeated applications within individual patients. Moreover, idarubicinol and idarubicin AUCs showed a good correlation with r=0.78, indicating that the interindividual variations of idarubicin AUC reflects differences in absorptions rather than metabolism. In order to describe the interindividual bioavailability of idarubicin - represented by AUC - measurement of a single data point with a high correlation with the AUC would be ideal. Our study demonstrates that the 24-h trough level shows such an excellent correlation (r=0.96) with AUC, making it the perfect candidate for fast estimates of the individual bioavailability in a given patient. On this basis, the longitudinal measurement of the 24-h trough level may allow the assessment of the impact of interindividual variations in AUC of clinical outcome and toxicity.
Collapse
Affiliation(s)
- E Schleyer
- Department of Hematology and Oncology, University of Göttingen, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|